FOBs: Industry Begins To Plot Course Along Pathway As It Awaits FDA Policy
Executive Summary
Everyone in the drug industry is eagerly waiting for any sign from FDA as to how it will handle biosimilar applications. So a recent meeting with a session devoted to FDA's current position on follow-on biologics was particularly tantalizing
You may also be interested in...
Under Pressure: Sanofi's Strategy Will Be Tested By Generic Lovenox Approval
Ahead of the big pharma's earnings call July 29, Sanofi-Aventis is under renewed pressure with Momenta and partner Sandoz promising a swift launch of their newly approved generic version of Lovenox.
Merck Prepares To Test Drive Biosimilar Pathway In The U.S.
Merck is gearing up to test the new regulatory pathway for biosimilar drugs in the U.S. and is hoping to be the first drug maker to move a biologic through the abbreviated process, Merck BioVentures President Michael Kamarck said in an interview June 28
Merck Prepares To Test Drive Biosimilar Pathway In The U.S.
Merck is gearing up to test the new regulatory pathway for biosimilar drugs in the U.S. and is hoping to be the first drug maker to move a biologic through the abbreviated process, Merck BioVentures President Michael Kamarck said in an interview June 28